Progress in culturing techniques, including the use of B-cell mitogens in combination with conventional cytogenetics, led to the discovery of non-random chromosomal abnormalities in chronic lymphocytic leukaemia (CLL), initially reported in 1980. [1] [2] [3] 
explained by a higher frequency of mutated immunoglobulin heavychain variable (IGHV) genes among patients with homozygous deletions (95%) compared with cases with only one deleted copy of 13q (73%). 13 However, a recent paper found no significant difference in time to first treatment (TTT) or overall survival (OS) when studying patients with heterozygous and homozygous 13q deletions. 25 Interestingly, the authors reported an association between the fraction of 13q-nuclei and clinical outcome, where patients carrying a high percentage of aberrant cells had a significantly shorter TTT, supporting similar findings in an earlier publication. 26 This indicates that there is probably more to the 13q-story than previously believed, and warrants further characterisation.
Deletion of 11q22-q23
A deletion in the long arm of chromosome 11 is the second most common chromosomal abnormality in CLL, with a frequency that is currently estimated to be around 12-18% of all patients 5, 11, 13 (see Figure 1 ). The minimal affected region is larger than that of the recurrent deletion in 13q and is mapped to a 2-3Mb region. 27, 28 There are several genes defined within this interval, with the ataxia telangiectasia mutated (ATM) gene being the most promising candidate. ATM is a key regulator of multiple signalling cascades that respond to DNA damage, and has been found to phosphorylate p53, thereby triggering the various p53-dependent signalling pathways. 29 In addition, both deletion and missense mutations of ATM have been found in T-cell pro-lymphocytic leukaemia and mantle cell lymphoma. [30] [31] [32] [33] Mutations in ATM have been reported in CLL, where they are predominantly found in 11q-deleted patients. [34] [35] [36] [37] [38] The prognostic relevance of 11q deletions in CLL was initially reported in the mid-1990s, when patients carrying this deletion were shown to have progressive disease and reduced survival. [39] [40] [41] These findings have since been confirmed in numerous studies, including a recent publication from our laboratory. 5, 13 In multivariate analysis, the presence of 11q deletion is a significant predictor of clinical outcome. 5 In addition, patients carrying an 11q deletion often display a distinctive clinical feature characterised by abdominal and mediastinal lymphadenopathy. 41 Interestingly, there is recent evidence that chemoimmunotherapy including rituximab may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with CLL. 42 
Trisomy 12
This recurrent chromosomal abnormality was the first and the most commonly detected aberration in the early days of CLL cytogenetics.
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Trisomy 12 is today detected in 11-16% of all patients with CLL, 5, 11, 13 although an early study using FISH on interphase cells reported a frequency as high as 35%. 44 
Deletion of 17p
Loss of 17p, which harbours the TP53 gene, is detected in up to 10%
of CLL patients, although a higher frequency is reported in fludarabine-refractory cases. 5, 11, 13, 54 In addition, the majority of patients displaying a 17p deletion also carry mutations on the remaining allele, whereas only up to 5% of non-17p-deleted cases are TP53-mutated. [55] [56] [57] In CLL, loss of 17p is associated with the worst survival and shortest TTT, as well as treatment failure with purine nucleoside analogues and alkylating agents. 5, 13, [58] [59] [60] [61] [62] Recent reports have also
shown an independent prognostic value of TP53 mutations without the accompanying deletion. 55, 63 In addition, TP53 abnormalities are further associated with disease transformation to diffuse large B-cell lymphoma (Richter's syndrome).
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Recurrent Genomic Aberrations in CLL -Implications for Disease Pathogenesis and Prognosis The current agents used in chemotherapy aim to interrupt the cell cycle or induce apoptosis through the p53 pathway, which in this group of patients is rendered non-functional. 65 Treatment with highdose methylprednisolone, a glucocorticoid that acts independently of the p53 pathway, has been shown to be effective in patients with p53 defects. 66 In addition, alternative treatment with the anti-CD52 monoclonal antibody alemtuzumab, which acts via complementdependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity, has shown promising results. [67] [68] [69] Finally, refractory patients who are deemed to be physically fit, particularly younger patients, may be considered for allogeneic stem cell transplantation. 70 In multivariate analysis of prognostic markers in CLL, deletion of 17p has repeatedly been shown to be one of the strongest independent markers of clinical outcome. 6, 7 Loss of 17p is most commonly associated with other poor prognostic markers, such as unmutated IGHV genes and advanced Binet stage. 6 However, a recent study by Best et al. reported a subset of CLL patients with TP53 abnormalities and mutated IGHV genes having stable disease for several years without any need for therapy. 71 We have found similar results in our laboratory (unpublished data). Thus, 17p abnormalities do not necessarily result in poor prognosis, and there seems to be a subgroup of patients who do not require treatment. This finding may argue against early introduction of chemotherapy in 17p-deleted patients without any clinical symptoms.
Deletions of 6q
Structural alterations in the long arm of chromosome 6 are commonly found in lymphoid malignancies. 72, 73 In CLL, a minimally deleted region has been defined in 6q21, and is reported in 6-7% of cases. 74, 75 In addition, a second recurrent deletion has been shown in 6q27. 75, 76 So far, no genes involved in the pathogenesis of CLL have been indicated for this region; however, absent in melanoma 1 (AIM1) has been suggested as a candidate gene. 12, 74, 77 Although several studies showed deletions in 6q to be associated with higher white blood cell counts and more extensive lymphadenopathy, which may serve as a marker of progression, the prognostic value of this structural aberration remains unclear due to conflicting reports. 75, 78, 79 We did not detect any deletions in 6q in a cohort of newly diagnosed CLL patients, which argues for this deletion as a marker of progression. The translocation involving the IGH and the BCL3 gene loci are present in various B-cell malignancies. They are most commonly found in CLL, where they are also associated with poor prognostic markers such as additional chromosomal changes, including trisomy 12 and unmutated IGHV genes. 90 In addition, this translocation has been reported primarily in patients carrying IGHV4-39/IGHD6-13/IGHJ5 rearrangements. 90 
Novel Recurrent Aberrations
The application of high-density single-nucleotide polymorphism (SNP) arrays for evaluation of genomic aberrations in CLL has in recent years resulted in the detection of several new recurrent abnormalities. These abnormalities include gain of 2p and 8q and deletion of 4p, 8p and 22q,
Haematological Malignancies Lymphoproliferative Disorders although most of them are detected at varying frequencies and their clinical relevance remains unclear. 10, 13, 91, 92 Gain of 2p, harbouring the MYCN oncogene, was recently found in up to 28% of untreated Binet stage B/C patients. 93 Importantly, this recurrent aberration is associated with increased MYCN messenger RNA (mRNA) expression, suggesting MYCN to have a pathogenic role in CLL. 93 Interestingly, we recently reported a small subgroup of CLL patients (n=5) with a detected gain in 2p to have a concurrent deletion of 11q and poor clinical outcome, requiring therapy. 13 Deletion of 22q was detected in 15% of cases analysed in a study by Gunn et al. 92 However, the authors found no association between del(22q) and clinical outcome. A number of subsequent studies using an alternative array platform have failed to detect this abnormality, perhaps due to the difference in array coverage. 10, 13 Finally, recurrent copy-number-neutral loss of heterozygosity (LOH), covering large parts of chromosome 13q, has been reported in patients with homozygous deletion of 13q14, although the clinical implication of this finding is still unknown.
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Genomic Complexity
The prognostic importance of genomic complexity in CLL was initially recognised in the mid-1980s, when increasing numbers of chromosomal aberrations within the cell clone were significantly associated with a poorer prognosis. 43, 95 Using CpG oligonucleotide-and CD40L-stimulated CLL cells and conventional cytogenetics, this association was further validated by Mayr et al. in 2006 . 83 In addition, a recent publication utilising high-density SNP arrays showed an association between genomic complexity, including non-recurrent changes in DNA copy number, and time to first and second treatment in CLL, where patients with two or more genomic aberrations had a significantly poorer clinical outcome. 96 Our own investigations using high-resolution SNP arrays have confirmed these findings. Furthermore, we detected that patients carrying deletions of 17p have a considerably higher frequency of larger genomic aberrations than do patients with other recurrent aberrations,
according to the hierarchal model defined by Döhner et al. 5, 13 (see Figure  2) . In fact, when investigating patients with four or more aberrations >5Mbp, 50% carried 17p deletions while the remaining cases all displayed deletions of 11q. In addition, more than 80% of cases with two to three copy-number alterations (CNAs) >5Mbp carried deletions of 11q, deletions of 17p or trisomy 12, while patients with no recurrent alterations or patients carrying 13q deletions mostly had zero to one CNAs >5Mbp, indicating an association between genomic complexity and more aggressive disease. Furthermore, our data indicated that nonrecurrent genomic aberrations <1Mbp in size did not carry prognostic information in CLL. 13 Thus, while genomic complexity is clinically relevant, FISH analysis of recurrent genomic aberrations would in most cases identify the poor-prognosis cases.
Concluding Remarks
Despite massive developments in the field of molecular genetics and molecular cytogenetics, the cause of CLL still remains unknown and, 
